View Clinical Trial (Medical Research Study)
Cancer Risk In Xeroderma Pigmentosum Heterozygotes
| City: |
|
Bethesda |
| State: |
|
Maryland |
| Zip Code: |
|
20892 |
| Conditions: |
|
Unspecified Adult Solid Tumor, Protocol Specific - Unspecified Childhood Solid Tumor, Protocol Specific |
| Purpose: |
|
RATIONALE: Screening individuals who have a xeroderma pigmentosum gene alteration may help
doctors identify persons at risk of developing cancer and identify other cancer genes.
PURPOSE: This clinical trial is comparing cancer risk in individuals who have a xeroderma
pigmentosum gene alteration to those who don't.
|
| Study Summary: |
|
OBJECTIVES:
- Compare risk of developing any type of cancer in participants who are heterozygous
carriers of xeroderma pigmentosum (XP) disease gene mutations vs non-carrier blood
relatives or spouses.
- Compare risk of developing skin cancers or cancers of the nervous system in these
participants.
- Compare cancer risk in different groups among heterozygous carriers of XP disease gene
mutations.
- Compare cancer risk in carriers of different XP disease gene mutations with
heterozygous carriers of these gene mutations.
OUTLINE: Participants undergo general cancer screening comprising a medical history and
physical examination, including a skin and neurologic examination. Laboratory samples are
collected for review.
Participants are followed annually by telephone or mail to determine clinical status.
PROJECTED ACCRUAL: Approximately 800 participants (400 heterozygous carriers and 400
non-carrier blood relatives or spouses) will be accrued for this study.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- One of the following:
- Blood relative of a patient diagnosed with xeroderma pigmentosum (XP)
- Spouse of a blood relative of a patient with XP
- Spouse of a patient with XP
- Family member of patient with clinical documentation of features of XP and
laboratory determination of DNA repair defect
- Evaluation of proband at the Warren Grant Magnuson Clinical Center or newly diagnosed
on other approved protocols (e.g., NCI-99-C-0099)
PATIENT CHARACTERISTICS:
Age
- Any age
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Able and willing to provide family history information
- Able and willing to provide tissue (skin, blood, buccal cells, or hair) for
laboratory studies
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
|
| NCT ID: |
|
NCT00049621 |
| Primary Contact: |
|
Study Chair Kenneth H. Kraemer, MD NCI - Dermatology Branch
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Bethesda, Maryland 20892 United States
Patient Recruitment Phone: 888-NCI-1937
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|